Capecitabine

Where the papers sit

18 papers from the last 6 months study capecitabine directly · updated from PubMed 3 Oct 2026

• Fluoropyrimidine Therapy Optimization

  Fluoropyrimidine therapy is moving toward dose tailoring, biomarker selection, and improved delivery across difficult solid tumors. DPYD variants and hemodialysis alter exposure and toxicity, while HER2-directed trastuzumab combinations seek tolerable treatment for frail gastric cancer patients. PARG-dependent RAD51AP1 stabilization identifies a potential mechanism of homologous-recombination-mediated chemoresistance. Lipid formulations and molecularly selected S-1 use broaden the effort beyond conventional dosing.

  6 papers · 33.3%

• Perioperative Pancreatic Cancer Therapy

  Neoadjuvant gemcitabine plus S-1 is being judged by recurrence-free survival and the ability to maintain perioperative dose intensity in pancreatic ductal adenocarcinoma. Nutritional change and chemotherapy-induced stromal remodeling are recurring determinants of treatment delivery and tumor behavior. Organotypic models add a mechanistic view of cancer-associated fibroblast responses. PRRT with CAPTEM extends the treatment question to pancreatic neuroendocrine tumors, leaving regimen selection disease-specific.

  4 papers · 22.2%

• Oral Chemotherapy Support

  Side-effect perception is being linked to safer self-management of oral anticancer therapy. Predictive models target unplanned acute care, while nutritional support during adjuvant S-1 chemotherapy is assessed against long-term outcomes and dose delivery. Gastrectomy patients recur as a setting where postoperative complications and acceptability shape treatment. The emphasis is shifting from prescribing alone toward monitoring, education, and practical support.

  3 papers · 16.7%

• Others — Fluoropyrimidine Treatment Across Cancers

  Fluoropyrimidines are being tested in maintenance, adjuvant, induction, and metastatic settings across breast, pancreatic, and nasopharyngeal cancers. In breast cancer, capecitabine is compared with fulvestrant and examined in early TNBC with BRCAm, while DPYD testing is weighed for safety and cost. S-1 and capecitabine combinations with taxanes or cisplatin target locally advanced disease. The varied endpoints—survival, recurrence, toxicity, and economic value—do not establish a single treatment direction.

  5 papers · 27.8%